Accueil / Tag Archives: Massachusetts

Tag Archives: Massachusetts

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Tuesday, May 23rd 2017 at 8:01pm UTC Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen’s focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.–(BUSINESS WIRE)– Debiopharm International SA (Debiopharm –, part of Debiopharm Group™, a Switzerland-based …

Plus »

Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer

Thursday, May 25th 2017 at 12:30pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Rita Jain, M.D. as Senior Vice President and Chief Medical Officer. …

Plus »

PureTech Health to Present at Jefferies 2017 Global Healthcare Conference

Thursday, May 25th 2017 at 6:00am UTC BOSTON–(BUSINESS WIRE)– PureTech Health plc (« PureTech », LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced that Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Thursday, …

Plus »

Sunovion Announces Utibron™ Neohaler® (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Tuesday, May 23rd 2017 at 1:18pm UTC – Presentations at the American Thoracic Society 2017 International Conference (ATS 2017) also included long-term safety data and pooled analyses of pivotal studies – MARLBOROUGH, Mass.–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced that multiple data analyses from two Phase 3 studies demonstrating that …

Plus »

X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of Its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma

Thursday, May 25th 2017 at 12:30pm UTC Phase 2 dose of X4P-001 in combination with Inlyta® selected from ongoing Phase 1/2 study CAMBRIDGE, Mass.–(BUSINESS WIRE)– X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced …

Plus »

Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals

Wednesday, May 24th 2017 at 2:00pm UTC LEXINGTON, Mass.–(BUSINESS WIRE)– Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) will acquire CTP-656 and other assets related to the …

Plus »

MetaStat Expands Therapeutic and Companion Diagnostic Intellectual Property Portfolio

Tuesday, May 23rd 2017 at 12:58pm UTC BOSTON–(BUSINESS WIRE)– MetaStat, Inc. (OTCQB: MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, announced today it received from the United States Patent and Trademark Office (USPTO), a notice of allowance for claims contained in a divisional application …

Plus »

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Pain Relief Technology

Monday, May 22nd 2017 at 4:07pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,656,070. The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation. This core technology enables several …

Plus »

Geneious Biologics to Power Better Biological Drug Development

Tuesday, May 23rd 2017 at 12:45pm UTC BOSTON–(BUSINESS WIRE)– BIO-IT WORLD – Geneious Biologics, an enterprise software solution for screening antibodies and related constructs using sequence data, was launched today and will change the way scientists identify antibodies for use in biological drug development. The Geneious Biologics software platform will …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous appréciez cet article ? Faites-nous part de vos commentaires.
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
Retrouvez nous sur
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...